Richard J. Lewis
Corporate Officer/Principal bij The University of Queensland
Actieve functies van Richard J. Lewis
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| The University of Queensland | Corporate Officer/Principal | 01-07-2009 | - |
| National Health & Medical Research Council | Corporate Officer/Principal | 01-07-2009 | - |
Loopbaan van Richard J. Lewis
Eerdere bekende functies van Richard J. Lewis
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Corporate Officer/Principal | 01-07-2009 | - |
Xenome Ltd.
 Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Hoofd Techniek/Wetenschap/O&O | 01-01-2000 | - |
| Oprichter | 08-02-2010 | - |
Statistieken
Internationaal
| Australië | 4 |
| Verenigde Staten | 2 |
Operationeel
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoraal
| Health Technology | 2 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Commercial Services |
| Bedrijven in privébezit | 2 |
|---|---|
Xenome Ltd.
Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
| National Health & Medical Research Council | Government |
- Beurs
- Insiders
- Richard J. Lewis
- Ervaring
